Research Paper Volume 15, Issue 21 pp 11891—11917
Comprehensive analysis reveals XCL2 as a cancer prognosis and immune infiltration-related biomarker
Figure 12. The gene set enrichment analysis of XCL2 in 12 cancers. The top 10 GSEA pathways of XCL2 in (A) BRCA, (B) CESC, (C) GBM, (D) KIRC, (E) LUSC, (F) PRAD, (G) SKCM, (H) STAD, (I) THCA, (J) THYM, (K) UCS, and (L) UVM. The Y-axis represents one gene set, and the X-axis is the distribution of enrichment corresponding to the core molecules in each gene set.